Astria Therapeutics, Inc.
ATXS
$4.04
$0.061.51%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 30.13% | 23.28% | 34.61% | 54.13% | 43.15% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 55.74% | 43.38% | 90.72% | 78.98% | 32.96% |
| Operating Income | -55.74% | -43.38% | -90.72% | -78.98% | -32.96% |
| Income Before Tax | 18.41% | -38.40% | -92.36% | -78.12% | -136.82% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 18.41% | -38.40% | -92.36% | -78.12% | -136.82% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 18.41% | -38.40% | -92.36% | -78.12% | -136.82% |
| EBIT | -55.74% | -43.38% | -90.72% | -78.98% | -32.96% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 48.69% | 32.89% | 4.57% | 4.82% | -19.55% |
| Normalized Basic EPS | 0.58% | 32.88% | 4.57% | 4.80% | 38.30% |
| EPS Diluted | 48.69% | 32.89% | 4.57% | 4.82% | -19.55% |
| Normalized Diluted EPS | 0.58% | 32.88% | 4.57% | 4.80% | 38.30% |
| Average Basic Shares Outstanding | 59.02% | 106.21% | 101.58% | 87.14% | 98.10% |
| Average Diluted Shares Outstanding | 59.02% | 106.21% | 101.58% | 87.14% | 98.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |